Interv Cardiol. 2009;1(1):51-62. Table 2 provides a listing of some of the bleeding definitions used in PCI clinical trials and registries. This table illustrates the wide spectrum of bleeding ...
Christian Ruff, MD, MPH, director of General Cardiology within the Cardiovascular Division at Brigham and Women’s Hospital and principal investigator of the AZALEA-TIMI 71 Study. The researchers found ...
Novel agent abelacimab has potential to be a safer anticoagulant, according to the randomized AZALEA-TIMI 71 trial. The trial had been stopped early because of a surprisingly large reduction in bleeds ...
An increasing number of reports have surfaced regarding interpatient variability of the platelet inhibitor properties of the thienopyridine, clopidogrel. From these reports, it appears that patients ...
An experimental anti-clotting medication, abelacimab, significantly reduced bleeding among people with atrial fibrillation (or AFib) who were at risk of stroke, according to results of the AZALEA-TIMI ...
Christian T. Ruff, MD, MPH, of Brigham and Women's Hospital, discusses new data comparing abelacimab with rivaroxaban in patients with atrial fibrillation presented at the American College of ...
In patients undergoing revascularization for left main coronary artery disease, CABG is associated with higher rates of all bleeds and in-hospital major bleeding, while PCI is linked to more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results